An announcement from Recursion Pharmaceuticals ( ($RXRX) ) is now available. On October 29, 2025, Recursion Pharmaceuticals announced that Roche ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated at ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...